Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

EOLS

Evolus Inc

May 17 • 04:00PM ET

13.59

Dollar change -0.11
Percentage change -0.80	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VHT VTWO IWC PTH ITOT VFMO

Index	RUT	P/E	-	EPS (ttm)	-1.05	Insider Own	21.18%	Shs Outstand	57.82M	Perf Week	6.59%
Market Cap	850.87M	Forward P/E	146.92	EPS next Y	0.09	Insider Trans	-2.23%	Shs Float	49.35M	Perf Month	17.56%
Income	-60.00M	PEG	-	EPS next Q	-0.05	Inst Own	79.31%	Short Float	9.68%	Perf Quarter	0.52%
Sales	219.70M	P/S	3.87	EPS this Y	55.00%	Inst Trans	0.63%	Short Ratio	7.46	Perf Half Y	52.53%
Book/sh	0.30	P/B	45.89	EPS next Y	132.84%	ROA	-31.06%	Short Interest	4.78M	Perf Year	37.55%
Cash/sh	1.55	P/C	8.78	EPS next 5Y	16.50%	ROE	-472.61%	52W Range	7.07 - 15.43	Perf YTD	29.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.81%	ROI	-41.69%	52W High	-11.94%	Beta	1.34
Dividend TTM	-	Quick Ratio	2.96	Sales past 5Y	44.65%	Gross Margin	66.85%	52W Low	92.22%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	3.21	EPS Y/Y TTM	18.05%	Oper. Margin	-15.05%	RSI (14)	62.09	Volatility	3.68% 3.95%
Employees	273	Debt/Eq	6.87	Sales Y/Y TTM	40.45%	Profit Margin	-27.31%	Recom	1.12	Target Price	22.29
Option/Short	Yes / Yes	LT Debt/Eq	6.81	EPS Q/Q	14.85%	Payout	-	Rel Volume	1.11	Prev Close	13.70
Sales Surprise	3.61%	EPS Surprise	45.49%	Sales Q/Q	42.21%	Earnings	May 07 AMC	Avg Volume	640.48K	Price	13.59
SMA20	8.62%	SMA50	3.99%	SMA200	24.42%	Trades		Volume	712,094	Change	-0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

May-16-24 02:54AM	Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS) (GuruFocus.com)
02:54AM	Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS) (GuruFocus.com)
May-15-24 08:30AM	Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit (Business Wire)
May-10-24 06:55PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:10AM	Evolus Sandra Beaver Named Orange County Business Journals Public Company CFO of the Year (Business Wire)
11:09AM	Loading…
May-08-24 11:09AM	Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:24AM	Q1 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
03:53AM	Evolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ... (GuruFocus.com)
May-07-24 08:58PM	EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:35PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:46PM	Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth (GuruFocus.com)
04:05PM	Evolus Reports First Quarter 2024 Results and Provides Business Update (Business Wire)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Apr-23-24 04:30PM	Evolus to Report First Quarter Financial Results on May 7, 2024 (Business Wire)
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
04:05PM	Loading…
Apr-17-24 04:05PM	Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for Extra-Strength 40U Formulation of Jeuveau (Business Wire)
Apr-12-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 08:00AM	Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 09:55AM	Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock (Business Wire)
Mar-08-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
03:24PM	Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:30PM	Q4 2023 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:34PM	Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 (GuruFocus.com)
09:53PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:30AM	Evolus Announces Results from European Head-to-Head Filler Trial (Business Wire)
Feb-27-24 08:30AM	Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences (Business Wire)
04:30PM	Loading…
Feb-22-24 04:30PM	Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 (Business Wire)
Feb-09-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-02-24 09:10PM	Evolus Inc Director Karah Parschauer Sells 11,931 Shares (GuruFocus.com)
Jan-16-24 05:28PM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance (Business Wire)
Jan-12-24 04:23PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-24 06:21PM	Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High? (Zacks)
Jan-04-24 04:05PM	Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications (Business Wire)
Dec-20-23 08:00AM	Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe (Business Wire)
Dec-08-23 04:30PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-23 09:08AM	Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 05:16PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-23 04:16PM	Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau (Business Wire)
Nov-06-23 08:45AM	Extra-Strength 40U Formulation of JeuveauDemonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting (Business Wire)
Nov-01-23 08:45AM	Evolus to Participate in November Investor Conferences (Business Wire)
Oct-25-23 08:45AM	Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting (Business Wire)
08:45AM	Evolus to Report Third Quarter 2023 Results (Business Wire)
Oct-08-23 06:41PM	7 Must-Own Small-Cap Stocks That Could Outperform the Market (InvestorPlace)
Sep-29-23 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-23 04:10PM	7 Small-Cap Stocks Analysts Predict Will Double in 2024 (InvestorPlace)
Sep-09-23 01:03PM	Insider Sell: CFO Sandra Beaver Sells 3,178 Shares of Evolus Inc (EOLS) (GuruFocus.com)
Sep-03-23 05:29AM	12 Cheapest and Best Countries for Plastic Surgery (Insider Monkey)
Aug-29-23 08:45AM	Evolus to Participate in September Conferences (Business Wire)
Aug-27-23 07:20PM	Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside Heres Why You Should Pay Attention (TipRanks)
Aug-23-23 06:53PM	Evolus Announces Inducement Grants for New Chief Marketing Officer (Business Wire)
Aug-21-23 08:45AM	Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer (Business Wire)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
08:45AM	Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers (Business Wire)
Aug-02-23 05:45PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Second Quarter 2023 Results and Provides Business Update (Business Wire)
Jul-27-23 11:42AM	Why Shares of Evolus Are Jumping Thursday (Motley Fool) +29.54%
08:45AM	Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue (Business Wire)
Jul-26-23 10:02AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:45AM	Evolus to Participate in Canaccord Genuitys 43rd Annual Growth Conference (Business Wire)
Jul-19-23 08:45AM	Evolus to Report Second Quarter 2023 Results and Provide Business Update (Business Wire)
Jul-15-23 07:30AM	Twitter Faces Threats From AI and Threads (Motley Fool)
Jun-29-23 09:00AM	Evolus Launches Nuceiva® (botulinum toxin type A) in Italy (Business Wire)
Jun-22-23 08:45AM	Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau ® (Business Wire)
Jun-08-23 04:05PM	Evolus Reaches 1 Million Redemptions in its Evolus Rewards Patient Loyalty Program (Business Wire)
Jun-02-23 06:38AM	Positive Signs As Multiple Insiders Buy Evolus Stock \ (Simply Wall St.)
May-16-23 01:44PM	Evolus (NASDAQ:EOLS) rallies 16% this week, taking three-year gains to 161% (Simply Wall St.) -5.91%
May-09-23 05:25PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Evolus Reports First Quarter 2023 Results and Provides Business Update (Business Wire)
04:01PM	Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse, a First-Generation Cold Technology HA by Symatese (Business Wire)
May-05-23 01:37PM	Evolus to Report First Quarter 2023 Results and Provide Business Update (Business Wire)
Apr-17-23 11:05AM	Evolus, Inc.'s (NASDAQ:EOLS) P/S Still Appears To Be Reasonable (Simply Wall St.)
Apr-04-23 10:39AM	Billionaire Israel Englander Goes Big on These 2 Strong Buy Stocks (TipRanks)
Mar-11-23 06:38AM	Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 10:12AM	Q4 2022 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-08-23 05:35PM	Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (Business Wire)
Feb-28-23 08:45AM	Evolus to Participate in the Barclays Global Healthcare Conference (Business Wire)
Feb-27-23 08:45AM	Evolus Initiates Nuceiva® Launch in Germany and Austria (Business Wire)
Feb-22-23 08:45AM	Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update (Business Wire)
Feb-10-23 11:07AM	Evolus Not Affected by Recent Korean Court Ruling (Business Wire)
Jan-31-23 08:45AM	Evolus to Participate in the SVB Securities Global Biopharma Conference (Business Wire) +5.80%
Jan-30-23 12:02PM	Institutional investors own a significant stake of 39% in Evolus, Inc. (NASDAQ:EOLS) (Simply Wall St.)
07:09AM	Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines (Benzinga)
Jan-28-23 08:00AM	"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance (Business Wire)
Jan-23-23 09:00AM	Evolus Receives Regulatory Approval for Nuceiva® in Australia (Business Wire)
08:00AM	Evolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress (Business Wire)
Jan-20-23 01:54PM	Why Evolus Shares Jumped This Week (Motley Fool) +5.04%
Jan-19-23 01:15PM	Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook (Benzinga) +5.31%
Jan-18-23 08:45AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration (Business Wire) +18.09%
Jan-03-23 10:03AM	Evolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To Profit (Simply Wall St.)
Dec-08-22 08:45AM	Evolus Extends Term of Credit Facility with Pharmakon Advisors (Business Wire) +7.65%
Dec-07-22 10:00AM	Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc. (PR Newswire)
09:17AM	Shareholders in Evolus (NASDAQ:EOLS) are in the red if they invested three years ago (Simply Wall St.)
Nov-10-22 05:57AM	Evolus Third Quarter 2022 Earnings: Revenues Disappoint (Simply Wall St.) +6.08%
Nov-08-22 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports Third Quarter 2022 Results and Provides Business Update (Business Wire)

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILL DAVID N	Director	May 14 '24	Sale	12.60	6,718	84,654	33,964	May 15 05:20 PM
Malik Vikram	Director	May 13 '24	Sale	12.93	28,000	362,012	254,014	May 15 05:19 PM
GILL DAVID N	Director	May 13 '24	Sale	12.72	3,643	46,356	40,682	May 15 05:20 PM
MOATAZEDI DAVID	See Remarks	May 10 '24	Sale	12.72	16,051	204,127	673,563	May 14 08:56 PM
Avelar Rui	See Remarks	May 10 '24	Sale	12.72	3,441	43,761	368,847	May 14 08:56 PM
Beaver Sandra	Chief Financial Officer	May 10 '24	Sale	12.72	2,423	30,814	151,778	May 14 08:55 PM
MOATAZEDI DAVID	See Remarks	Mar 27 '24	Sale	13.86	6,236	86,431	689,614	Mar 29 07:08 PM
MOATAZEDI DAVID	See Remarks	Mar 19 '24	Sale	13.92	96,566	1,344,604	695,850	Mar 21 06:08 PM
Avelar Rui	See Remarks	Mar 19 '24	Sale	13.92	27,603	384,350	372,288	Mar 21 06:09 PM
Beaver Sandra	Chief Financial Officer	Mar 19 '24	Sale	13.92	5,672	78,978	154,201	Mar 21 06:09 PM
MOATAZEDI DAVID	See Remarks	Feb 22 '24	Sale	13.08	7,706	100,804	792,416	Feb 23 08:27 PM
Beaver Sandra	Chief Financial Officer	Feb 22 '24	Sale	13.08	1,821	23,821	159,873	Feb 23 08:27 PM
Avelar Rui	See Remarks	Feb 22 '24	Sale	13.08	1,821	23,821	399,891	Feb 23 08:27 PM
Parschauer Karah Herdman	Director	Jan 30 '24	Sale	13.14	11,931	156,733	31,243	Feb 02 04:57 PM
MOATAZEDI DAVID	See Remarks	Dec 08 '23	Sale	9.73	31,300	304,505	603,944	Dec 08 06:15 PM
MOATAZEDI DAVID	See Remarks	Dec 06 '23	Sale	10.09	51,348	517,891	635,244	Dec 08 06:15 PM
Medytox Inc.	Former 10% Owner	Oct 16 '23	Sale	7.50	1,690,663	12,679,972	3,381,326	Oct 18 04:21 PM
Beaver Sandra	Chief Financial Officer	Sep 06 '23	Sale	9.70	3,178	30,827	113,368	Sep 08 08:54 PM
MOATAZEDI DAVID	See Remarks	Aug 16 '23	Sale	10.27	14,778	151,770	686,592	Aug 16 08:25 PM
Beaver Sandra	Chief Financial Officer	Aug 16 '23	Sale	10.27	2,211	22,707	116,546	Aug 16 08:25 PM
Avelar Rui	See Remarks	Aug 16 '23	Sale	10.27	2,211	22,707	353,386	Aug 16 08:25 PM
Malik Vikram	Director	Aug 15 '23	Buy	7.41	174,967	1,296,505	275,550	Aug 15 04:34 PM

Open in Screener

YMAB

Y-Mabs Therapeutics Inc

May 17 • 04:00PM ET

11.60

Dollar change -0.25
Percentage change -2.11	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

YMAB Y-Mabs Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWN VTWO VHT IWO SCHA IWC

Index	RUT	P/E	-	EPS (ttm)	-0.50	Insider Own	24.37%	Shs Outstand	43.67M	Perf Week	-5.54%
Market Cap	509.01M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	2.40%	Shs Float	33.19M	Perf Month	-22.67%
Income	-21.67M	PEG	-	EPS next Q	-0.11	Inst Own	55.64%	Short Float	7.47%	Perf Quarter	-28.79%
Sales	84.50M	P/S	6.02	EPS this Y	11.22%	Inst Trans	-3.46%	Short Ratio	6.67	Perf Half Y	120.95%
Book/sh	2.26	P/B	5.13	EPS next Y	30.65%	ROA	-16.62%	Short Interest	2.48M	Perf Year	21.59%
Cash/sh	1.73	P/C	6.72	EPS next 5Y	-	ROE	-20.93%	52W Range	4.60 - 20.90	Perf YTD	70.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.06%	ROI	-21.78%	52W High	-44.50%	Beta	0.67
Dividend TTM	-	Quick Ratio	5.67	Sales past 5Y	37.03%	Gross Margin	86.41%	52W Low	152.17%	ATR (14)	1.06
Dividend Ex-Date	-	Current Ratio	6.15	EPS Y/Y TTM	70.66%	Oper. Margin	-29.68%	RSI (14)	30.78	Volatility	6.47% 7.18%
Employees	100	Debt/Eq	0.01	Sales Y/Y TTM	12.62%	Profit Margin	-25.64%	Recom	1.86	Target Price	21.14
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-3.49%	Payout	-	Rel Volume	1.02	Prev Close	11.85
Sales Surprise	-12.50%	EPS Surprise	-10.29%	Sales Q/Q	-1.58%	Earnings	May 07 AMC	Avg Volume	371.80K	Price	11.60
SMA20	-20.91%	SMA50	-23.08%	SMA200	21.22%	Trades		Volume	379,936	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-23	Upgrade	Wedbush	Neutral → Outperform	$5 → $13
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$4
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral	$23 → $5
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral	$6
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight	$16 → $7
Jul-06-22	Resumed	Canaccord Genuity	Buy	$35
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$27
Feb-03-22	Resumed	Guggenheim	Buy	$22
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$25
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral	$57 → $30
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight	$57 → $52
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral	$56
Nov-09-20	Reiterated	H.C. Wainwright	Buy	$52 → $65
May-05-20	Initiated	Barclays	Overweight	$44
May-01-20	Initiated	Janney	Buy

Show Previous Ratings

May-09-24 11:58AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.44%
03:04AM	Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 09:57PM	Q1 2024 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -20.92%
May-07-24 09:55PM	YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:12PM	Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates (GuruFocus.com)
05:55PM	Loading…
05:55PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
Apr-26-24 07:05AM	Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 (GlobeNewswire)
Apr-25-24 04:05PM	Y-mAbs to Present at 2024 ASCO Annual Meeting (GlobeNewswire)
Mar-28-24 09:55AM	Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet (Zacks)
Mar-20-24 07:37AM	YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Mar-14-24 09:05AM	Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer (GlobeNewswire) -5.30%
Mar-12-24 09:55AM	Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High? (Zacks)
Mar-05-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice (Zacks)
Mar-04-24 08:45AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript (Insider Monkey) -7.28%
07:30AM	Loading…
07:30AM	Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors (GlobeNewswire)
Mar-01-24 09:42PM	Q4 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.92%
Feb-29-24 05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:37PM	Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-22-24 10:00AM	Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 07:30AM	Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 (GlobeNewswire)
Feb-13-24 04:10AM	Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Jan-02-24 04:05PM	Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-23 04:05PM	Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index (GlobeNewswire)
Dec-12-23 01:05AM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (GuruFocus.com)
Dec-03-23 03:04AM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (GuruFocus.com)
Nov-30-23 11:04PM	Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB) (GuruFocus.com)
Nov-15-23 01:14PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript (Insider Monkey)
01:33AM	Q3 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
05:31PM	Loading…
Nov-13-23 05:31PM	Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational Streamlining (GuruFocus.com)
05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Nov-08-23 12:00PM	All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy (Zacks)
Oct-31-23 07:05AM	Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023 (GlobeNewswire)
Oct-18-23 04:05PM	Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director (GlobeNewswire)
Oct-17-23 04:05PM	Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA (GlobeNewswire)
Oct-16-23 04:05PM	Y-mAbs Announces Publication in Cancers (GlobeNewswire)
Sep-21-23 04:05PM	Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology (GlobeNewswire)
Sep-06-23 04:05PM	Y-mAbs to Participate at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-23-23 09:55AM	Wall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet (Zacks)
Aug-13-23 06:25AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 05:15PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.48%
04:05PM	Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Aug-02-23 04:05PM	Y-mAbs to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-01-23 04:05PM	Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023 (GlobeNewswire)
Jul-26-23 12:35PM	Institutional owners may take dramatic actions as Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent 13% drop adds to one-year losses (Simply Wall St.)
Jun-02-23 03:15PM	Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week (Simply Wall St.) +5.01%
May-26-23 09:00AM	Y-mAbs Announces Presentation of Naxitamab Data at ASCO (GlobeNewswire)
09:00AM	Y-mAbs Announces Presentation of GD2-SADA Study at ASCO (GlobeNewswire)
May-23-23 09:00AM	Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil (GlobeNewswire)
May-18-23 06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research) +8.39%
May-13-23 08:18AM	New Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) (Simply Wall St.)
May-10-23 06:14AM	Y-mAbs Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.) +7.26%
02:52AM	Q1 2023 Y-mAbs Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance (GlobeNewswire)
May-01-23 10:01AM	Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-28-23 09:00AM	Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 (GlobeNewswire) +5.46%
Apr-18-23 09:00AM	Y-mAbs Announces Presentation of Naxitamab data at AACR (GlobeNewswire)
Apr-17-23 10:57AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Surges 104% Yet Its Low P/S Is No Reason For Excitement (Simply Wall St.)
Apr-05-23 07:44PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade (Zacks)
09:00AM	Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA (GlobeNewswire)
Apr-04-23 05:12AM	Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Mar-30-23 05:25PM	Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:01PM	Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
02:42PM	Dow futures down 0.1%, Virgin Orbit tanks 41.2% after-hours (Investing.com)
Mar-21-23 04:01PM	Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023 (GlobeNewswire)
Mar-15-23 10:22AM	Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Feb-20-23 10:00AM	Analysts Estimate Apellis Pharmaceuticals, Inc. (APLS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-16-23 10:01AM	Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks) -8.37%
07:57AM	With 51% ownership, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) boasts of strong institutional backing (Simply Wall St.)
Feb-02-23 09:00AM	Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab (GlobeNewswire)
Jan-05-23 10:34AM	Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce (Benzinga) -7.83%
Jan-04-23 04:01PM	Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA (GlobeNewswire) +6.24%
Jan-03-23 09:00AM	Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 09:00AM	Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe (GlobeNewswire)
Dec-16-22 04:01PM	The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe (GlobeNewswire)
Dec-14-22 09:00AM	Y-mAbs Announces Pipeline Update (GlobeNewswire)
Dec-08-22 09:00AM	Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China (GlobeNewswire)
Dec-07-22 09:19AM	Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) are in the red if they invested three years ago (Simply Wall St.) +7.42%
Dec-06-22 09:00AM	Y-mAbs to Host Annual Research and Development Day in New York (GlobeNewswire)
Dec-01-22 05:34PM	Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application (GlobeNewswire)
Nov-07-22 05:15PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
Nov-02-22 04:01PM	Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022 (GlobeNewswire)
Oct-31-22 03:01PM	Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful (Benzinga) -59.57%
08:52AM	Y-mAbs Therapeutics shares fall 42% following last week's FDA advisory committee vote (MarketWatch)
05:34AM	FDA's AdComm Gives Thumbs Down To Pediatric Cancer Therapy (Benzinga)
Oct-28-22 03:33PM	Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab (GlobeNewswire)
Oct-06-22 09:34AM	Here's Why We're Watching Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation (Simply Wall St.)
Oct-03-22 09:00AM	Y-mAbs Announces Pivotal Data for Omburtamab (GlobeNewswire) -7.91%
Sep-29-22 02:53AM	YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-22 09:00AM	Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil (GlobeNewswire)
Sep-09-22 08:35AM	With 55% ownership of the shares, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is heavily dominated by institutional owners (Simply Wall St.)
Sep-01-22 04:05PM	Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab (GlobeNewswire)
Aug-30-22 09:00AM	Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma (GlobeNewswire)
Aug-13-22 08:29AM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Analysts Just Slashed This Year's Estimates (Simply Wall St.)
Aug-08-22 05:45PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates (Zacks)

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gad Thomas	CHIEF BUSINESS OFFICER	Mar 05 '24	Sale	16.44	3,900	64,116	158,700	Mar 07 05:01 PM
Rajah Vignesh	SVP & CHIEF MEDICAL OFFICER	Mar 05 '24	Sale	16.53	1,711	28,283	33,889	Mar 07 05:02 PM
Smith Susan Laura	SVP & CHIEF COMMERCIAL OFFICER	Mar 05 '24	Sale	16.55	1,682	27,837	33,918	Mar 07 04:59 PM
Gad Thomas	Chief Business Officer	Dec 21 '23	Option Exercise	2.00	50,000	100,000	140,500	Dec 26 04:15 PM
Gad Thomas	Chief Business Officer	Dec 15 '23	Sale	6.61	50,000	330,500	265,032	Dec 15 07:40 PM
Gad Thomas	Chief Business Officer	Dec 14 '23	Sale	6.83	50,000	341,500	315,032	Dec 15 07:40 PM
Gad Thomas	Chief Business Officer	Dec 13 '23	Sale	6.58	50,000	329,000	365,032	Dec 15 07:40 PM
WG Biotech ApS	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233	Dec 12 08:26 AM
WG Biotech ApS	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233	Dec 12 08:27 AM
WG Biotech ApS	Director	Dec 08 '23	Buy	6.99	18,503	129,379	4,449,915	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 08 '23	Buy	6.99	18,503	129,379	4,449,915	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Dec 07 '23	Buy	6.50	6,183	40,190	4,431,412	Dec 11 05:25 PM
WG Biotech ApS	Director	Dec 07 '23	Buy	6.50	6,183	40,190	4,431,412	Dec 11 05:25 PM
Wedell-Wedellsborg Johan	Director	Nov 29 '23	Buy	5.97	51,837	309,477	4,425,229	Dec 01 05:14 PM
WG Biotech ApS	Director	Nov 29 '23	Buy	5.97	51,837	309,477	4,425,229	Dec 01 05:15 PM
WG Biotech ApS	Director	Nov 28 '23	Buy	5.81	30,671	178,275	4,373,392	Nov 29 05:14 PM
Wedell-Wedellsborg Johan	Director	Nov 28 '23	Buy	5.81	30,671	178,275	4,373,392	Nov 29 05:15 PM
Wedell-Wedellsborg Johan	Director	Nov 27 '23	Buy	5.49	62,516	343,019	4,342,721	Nov 29 05:15 PM
WG Biotech ApS	Director	Nov 27 '23	Buy	5.49	62,516	343,019	4,342,721	Nov 29 05:14 PM
Gad Thomas	Chief Business Officer	Nov 21 '23	Sale	5.31	75,000	397,988	415,032	Nov 22 05:00 PM
Gad Thomas	Chief Business Officer	Nov 20 '23	Sale	5.30	75,000	397,395	490,032	Nov 22 05:00 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

EOLS

Evolus Inc

YMAB

Y-Mabs Therapeutics Inc

Upgrade your FINVIZ experience